Rituximab for HTLV-1-associated Myelopathy

Phase 2 Unknown 100 enrolled First Affiliated Hospital of Fujian Medical University

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Neuroprotective or anti-inflammatory strategies are invaluable in HTLV-1-associated myelopathy due to its rapid progression. We evaluated the efficacy of rituximab in patients with HTLV-1-associated myelopathy.

Timeline

Start: 2019-08-15
Primary completion: 2023-07
Completion: 2024-07

Publications

Lv A, Fang Y, Lin X, Chen J, Song H, Wang N, Chen WJ, Fu Y, Li R, Lin Y. B-cell depletion limits HTLV-1-infected T-cell expansion and ameliorate HTLV-1-associated myelopathy. Ann Clin Transl Neurol. 2024 Oct;11(10):2756-2768. doi: 10.1002/acn3.52190. Epub 2024 Aug 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	100 mg	Intravenous

Rituximab for HTLV-1-associated Myelopathy

Summary

Timeline

Publications

Drugs

Indications